Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (9505)	11/17/2003 8:15:37 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

We do not know that! High % for placebo (55%) screwed up Aptamer results. Wasn't this simply a result of the patients selected for the trial. They had worse vision (as bad as 20/320) and larger lesion sizes (closer to blindness endpoint). Thus whether or not they were treated it was more difficult for them to lose another 3 lines of vision. Seems to me that Macugen is quite likely to yield marginal results at best and has a very dangerous side effect profile. At best, it was a poorly designed trial and may have to be repeated should the companies still believe that their drug has any potential. IMHO, Ian